The New York Times profiles Doustdar a year into the Novo Nordisk turnaround

The New York Times published a profile on September 1, 2026, of Novo Nordisk chief executive Mike Doustdar, marking roughly one year into his effort to turn around the company behind Ozempic and Wegovy.^[1] The piece was reported from New York and from Clayton and Durham, North Carolina, and laid out Doustdar's central argument: that investors have become fixated on Novo Nordisk's rivalry with Eli Lilly and are underestimating the breadth of Novo Nordisk's broader drug portfolio and its pipeline of future treatments.^[1]

A key theme of the profile is that pills, not injections, may be the company's next major growth chapter. The Times framed oral GLP-1 medicines as Novo Nordisk's likely "second act" after the success of the Ozempic injection.^[1] The article does not specify, at least in the material available, exact sales figures, drug names beyond Ozempic, or a timeline for any new pill launch, so those details are not yet known from this reporting.^[1]

Underneath the turnaround narrative, the profile captured a specific worry among investors: the key US patent covering semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, expires early in the next decade.^[1] The article does not give the precise year, but frames this patent cliff as a central piece of the anxiety weighing on the company's stock and long-term outlook.^[1] Once that patent lapses, generic and lower-cost versions of semaglutide could become available in the US, though the exact timing and market effects are not detailed in this reporting.^[1]

Why it matters for patients

For people currently taking Ozempic, Wegovy, or Rybelsus, the profile is less about a specific product change and more about the company's long-term direction. If Novo Nordisk's pipeline of pills and other treatments succeeds as Doustdar argues, patients could eventually have more options for how they take a GLP-1 medicine, including non-injectable choices beyond the currently available Rybelsus tablet.^[1] The profile does not describe new pill products by name or give a launch date, so patients should not expect immediate changes to their prescriptions based on this article alone.^[1]

The semaglutide patent expiration mentioned in the profile is potentially the most consequential fact for patients long-term. Patent expiration is often the step that opens the door to generic competition, which historically can lower prices once it occurs. But the Times piece frames this as a future event, expected early in the next decade, not something happening now.^[1] Patients concerned about cost today should know that this development does not change current pricing, insurance coverage, or availability of Ozempic, Wegovy, or Rybelsus.

The profile's broader message, that investors may be too narrowly focused on the Novo Nordisk versus Eli Lilly rivalry, does not translate into a specific action patients need to take.^[1] It reflects how Wall Street is assessing the company's health, not a change to the drugs themselves, their approved uses, or their safety profiles.

What happens next

The Times profile does not specify near-term dated milestones for new pill launches or regulatory filings.^[1] The article does point to the semaglutide patent expiring early in the next decade as a fixed point investors are watching, though the exact date is not given in the available reporting.^[1] Further detail on Novo Nordisk's pipeline, any new pill candidates, and their development timelines was not available in the source material reviewed for this article, so those specifics remain unknown for now.^[1]